NeoTAILOR: ABiomarker-directed Approach to Guide Neoadjuvant Therapy for Patients With Stage II/III ER-positive, HER2-negative Breast Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Nusayba Bagegni, M.D.
Washington University School of Medicine
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Washington University School of Medicine
St Louis, Missouri, United States
Carolina Salvador, M.D.Cynthia X Ma, M.D., Ph.D.Debbie L Bennett, M.D.Emily L Podany, M.D.Fouad Boulos, M.D.Ian Hagemann, M.D., Ph.D.Jingqin (Rosy) Luo, Ph.D.John Olson, M.D., Ph.D.Katherine Glover-Collins, M.D., Ph.D.Katherine Weilbaecher, M.D.Nusayba A Bagegni, M.D.Recruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 May 2024
- Primary completion
- 30 Nov 2027
- Completion
- 30 Nov 2027
- Last update posted
- 13 Apr 2026
- Registered enrollment
- 81
- Registry id
- NCT05837455
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.